Nebulised drugs in palliative care

S Ahmedzai, C Davis

Palliative care is now generally accepted as being the multidisciplinary care of patients with advanced, progressive, and ultimately fatal diseases which are likely to lead to death within about 12 months and in whom the focus of care is on the quality of life. Most of the patients who fall into this category have metastatic malignancy, but it also includes those with motor neurone disease and other neuromuscular conditions, HIV/AIDS, end stage cardiac or respiratory failure, and renal failure.

Palliative care is given in the community in the UK by general practitioners and district nurses, and in hospitals by staff from several disciplines, notably oncology/radiotherapy and general/respiratory medicine. The term “specialist palliative care” is reserved for the involvement of hospices, or trained and accredited medical and nursing teams in hospitals and the community (including day centres). Many specialist palliative care teams have access to physiotherapy, although this is less likely to be available in the community.

The general condition and age of the patients and, in general, the lack of training in respiratory management among palliative care staff mean that, in this clinical setting, some points need particular attention.

In the setting of palliative care the main conditions which might benefit from nebuliser therapy are dyspnoea, cough (both unproductive and with copious sputum), and pooling of saliva in the hypopharynx and consequent aspiration, such as occurs in patients with motor neurone disease or bulbar palsy. History and clinical examination are of vital importance in establishing the most likely pathological causes of breathlessness in each patient. A chest radiograph can also be helpful but it is not always possible or appropriate to perform one.

There is very little scientific evidence to support the use of nebulised drugs in the symptomatic management of patients with breathlessness and cough related to primary or secondary malignancy (table 1), or in chronic cardiac and neuromuscular disorders. Doses and schedules have been partly derived from experience in patients with chronic lung disease but mainly empirically from practitioners’ experiences.

In the setting of palliative care it is easy to commence drug therapy but much harder to discontinue it. Ideally, a therapeutic trial should be conducted but it is difficult to generalise and propose a fixed duration of such a trial. However, we recommend that all newly initiated treatments should be considered as therapeutic trials and be reviewed by experienced staff within three days so that adjustments can be made or treatment stopped. It is not usually appropriate to ask the primary care team to review if treatment with a nebulised opioid or a local anaesthetic has been started.

### Table 1 Nebulised drugs used in patients with cough and/or breathlessness related to cancer

<table>
<thead>
<tr>
<th>Class of drugs</th>
<th>Indication</th>
<th>Scientific evidence</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal saline</td>
<td>Loosening of tenacious secretions</td>
<td>None</td>
<td>Probably underemployed in this setting. May also help breathlessness due to pooling of saliva in the hypopharynx and consequent aspiration. May not be more beneficial than use of a mouthpiece to a mask which can generate a feeling of claustrophobia. If a mouthpiece is used the patient must breathe through the mouth. Nebulised drugs are usually ineffective in extremely breathless patients with minimal inspiratory effort. The position of the patient is important. He or she should ideally be sitting upright or at least at 45° during nebulisation. If the patient cannot be moved from the supine position then administration of</td>
</tr>
<tr>
<td>Macrolide agents e.g. hypertonic saline, acetylcysteine</td>
<td>Possibly in emirse, lymphangitis, radiation pneumonitis and cough after insertion of stents</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Steroids e.g. budesonide</td>
<td>Possibly non-specific effects on breathlessness. May be useful in some cases with cough, particularly lymphangitis</td>
<td>Conflicting evidence: no specific effects on COPD</td>
<td></td>
</tr>
<tr>
<td>Local anaesthetics e.g. lignocaine, bupivacaine</td>
<td>Possibly non-specific effects on breathlessness. May be useful in some cases with cough, particularly lymphangitis</td>
<td>Conflicting evidence: no specific effects on breathlessness</td>
<td></td>
</tr>
<tr>
<td>Opioids e.g. morphine, diamorphine, fentanyl</td>
<td>Treatment of reversible airway obstruction extrapolated from patients with asthma and COPD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bronchodilators e.g. salbutamol</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Practical considerations

Particle size may not be as critical as it is in some other situations but, nonetheless, clinicians must be aware of the range of compressors and nebulisers available and the variation in their performance. A jet nebuliser driven by an electric/battery operated compressor is usually portable and is preferred by patients. A jet nebuliser has the advantage of producing a droplet size of less than 5 µm which can penetrate alveoli but it is not always possible or appropriate to perform one.

Correspondence to: Professor S Ahmedzai.
Ahmedzai, Davis

Drugs used by this route is impractical and probably inappropriate.

Nebulisers are being used increasingly in palliative care settings which do not have the infrastructure for a nebuliser service. Some practical considerations can be overlooked. The following are essential: education of patients and carers; instruction on cleaning of equipment including "disposables"; a system that ensures regular maintenance and electrical safety of equipment; and arrangements for collection of the equipment after a patient's death. Doctors who prescribe nebuliser treatment at home or in hospices should consider collaborating with their local nebuliser service on these issues.

Drugs used
The drugs most commonly used in this setting are described in table 1. Since the use of nebulised local anaesthetics and nebulised opioids is largely peculiar to palliative care, these interventions are discussed in more detail below.

Nebulised local anaesthetics
One study showed a ventilatory stimulant effect in normal volunteers but studies to date do not support the use of nebulised local anaesthetics for breathlessness in patients with chronic obstructive pulmonary disease (COPD). In a recent randomised study of palliative care, patients with cancer showed no benefit from nebulised lignocaine compared with normal saline. The only study to investigate the efficacy of local anaesthetics in the treatment of cough showed encouraging results and there are unpublished anecdotal reports of its use in patients with cough of various causes (table 1). A dose of nebulised local anaesthetic before returing at night can be very helpful in reducing cough stimulated by pooling of saliva in the hypopharynx of patients with motor neurone disease or multiple sclerosis but may increase the risk of aspiration. The relative merits of lignocaine and bupivacaine have not been assessed. The reduced sensitivity of the cough reflex means that patients should fast for one hour after treatment with a local anaesthetic. Bronchospasm is not uncommon and may be of delayed onset— that is, after repeated doses. The patient and his/her family must be warned of this potential complication and the first dose should be given in a supervised setting where medical or nursing intervention is available if necessary. The treatment should be reviewed regularly. In asthmatic patients it may be used to prescribe a bronchodilator routinely before treatment.

Nebulised opioids
Nebulised opioids are used to improve patient care but only one paper has been published to support the use of nebulised morphine in breathless patients with COPD and these findings were not substantiated in two subsequent studies.

There is increasing anecdotal evidence to support their use in patients with breathlessness related to cancer, and it has been suggested that patients with lymphangitis are most likely to derive benefit. However, a recent randomised placebo controlled trial failed to show a significant effect, although some patients may benefit.

Various opioid drugs have been used of which morphine and diamorphine are the most common; fentanyl may be associated with less bronchospasm. Morphine 6-glucuronide, codeine and hydromorphone have also been used. None of these drugs is licensed for administration by nebuliser in the UK.

For all these drugs there is no consensus on the most appropriate starting dose or schedule, the best steps for dose titration, or on the optimal design and length of a therapeutic trial. It is usually assumed that equianalgesic doses of different opioids will have similar effects on the symptom of breathlessness, but there is no scientific evidence to support this premise.

The pharmacokinetics of nebulised opioids have been investigated. There is some evidence that the bioavailability of nebulised morphine in normal volunteers is very low (<5%) relative to the intravenous route. It is, however, dangerous to assume that this is always the case because the systemic bioavailability of any nebulised drug can vary considerably depending on the equipment used and the degree of inspiratory effort of which the patient is capable. Thus, the simultaneous use of both nebulised and oral or subcutaneous opioids may carry a risk of cumulative toxicity proportional to the dose of nebulised opioid administered.

Nebulised opioids are unlikely to have a place in the management of pain and, in any case, the oral, rectal and subcutaneous routes are more appropriate. There is a risk of bronchospasm, particularly with higher doses. The first dose should always be administered in a supervised setting where medical or nursing intervention is available in case of bronchospasm or other adverse effect. Some, but not all, clinicians use preservative-free opioid preparations in an attempt to reduce the risk of bronchospasm. If morphine is employed then the intravenous formulation should be used and not the oral elixir.

In the domiciliary setting the problems of preparation of the nebuliser solution (use of controlled drugs in glass vials, need to mix with saline) should not be underestimated. Difficulties may arise if patients travel on holiday (especially abroad) and need to take a nebuliser and opioid ampoules—a letter of authorisation should be given and an adequate supply dispensed before departure.

Further research
There are several areas where our knowledge about nebuliser usage in palliative care is weak or altogether lacking. It is cause for concern that many teams and units worldwide are using nebuliser therapy increasingly, and possibly uncritically, while the evidence for benefit from the
Table 2  Current “best clinical practice” for the use of nebulised drugs in palliative care

<table>
<thead>
<tr>
<th>Indication</th>
<th>Drug</th>
<th>Starting dose/schedule</th>
<th>Dose titration</th>
<th>Special points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tenacious secretions</td>
<td>Normal saline</td>
<td>5 ml 6 hourly</td>
<td>Up to 2 hourly</td>
<td>Risk of sensitivity to cardiac stimulant effects</td>
</tr>
<tr>
<td>Reversible airflow obstruction</td>
<td>Terbutaline</td>
<td>2.5 mg 4–6 hourly</td>
<td>Up to 5 mg 4 hourly</td>
<td>Risk of oral candidiasis, rinse mouth after use</td>
</tr>
<tr>
<td></td>
<td>Budesonide* (in conjunction with other appropriate oral/parenteral treatment)</td>
<td>0.5 mg 12 hourly</td>
<td>Up to 1 mg 12 hourly</td>
<td>Risk of oral candidiasis, rinse mouth after use</td>
</tr>
<tr>
<td>Cough</td>
<td>Salbutamol</td>
<td>2.5 mg 4–6 hourly</td>
<td>Up to 5 mg 4 hourly</td>
<td>Risk of bronchospasm, Fast for one hour after nebulisation</td>
</tr>
<tr>
<td></td>
<td>Budesonide* (in conjunction with other appropriate oral/parenteral treatment)</td>
<td>0.5 mg 12 hourly</td>
<td>Up to 1 mg 12 hourly</td>
<td>Risk of bronchospasm, Fast for one hour after nebulisation</td>
</tr>
<tr>
<td></td>
<td>Corticosteroids</td>
<td>Up to 10 mg 4 hourly</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Morphine sulphate</td>
<td>Up to 100 µg 4 hourly</td>
<td></td>
<td>Risk of bronchospasm, Fast for one hour after nebulisation</td>
</tr>
<tr>
<td></td>
<td>Diamorphine*</td>
<td>Up to 100 µg 4 hourly</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bupivacaine*</td>
<td>Up to 200 µg 2 hourly</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Not licensed indication.

Nebulised drugs in palliative care

indications that potent drugs being used is as yet predominantly anecdotal. Many of the studies so far published have tended to focus on objective and possibly irrelevant functional improvements rather than validated and clinically meaningful subjective and quality of life indicators. Longitudinal studies are, however, difficult to perform in this population of patients since their clinical condition often changes rapidly and attrition rates are high.

Recommendations for best clinical practice

Our recommendations are presented in table 2.


Nebulised drugs in palliative care

S Ahmedzai and C Davis

Thorax 1997 52: 75
doi: 10.1136/thx.52.2008.S75

Updated information and services can be found at:
http://thorax.bmj.com/content/52/suppl_2/75.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/